Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
36.98M | 35.00M | 371.21M | 436.00K | 913.08M | 543.00K | Gross Profit |
-88.65M | -75.25M | 240.96M | -109.81M | 895.13M | -268.86M | EBIT |
-474.40M | -466.57M | -222.54M | -673.16M | 373.53M | -354.44M | EBITDA |
-455.24M | -447.31M | -202.70M | -648.99M | 391.48M | -345.25M | Net Income Common Stockholders |
-385.66M | -366.25M | -153.61M | -650.17M | 377.66M | -348.87M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.86B | 1.90B | 1.69B | 1.82B | 2.38B | 1.69B | Total Assets |
2.17B | 2.24B | 2.23B | 2.24B | 2.75B | 1.83B | Total Debt |
219.36M | 223.69M | 238.63M | 244.02M | 225.03M | 61.43M | Net Debt |
-15.83M | -74.56M | -150.84M | 32.14M | -698.00M | -1.11B | Total Liabilities |
336.94M | 309.95M | 346.77M | 367.58M | 352.42M | 163.73M | Stockholders Equity |
1.83B | 1.93B | 1.88B | 1.88B | 2.40B | 1.66B |
Cash Flow | Free Cash Flow | ||||
-307.86M | -144.68M | -272.35M | -532.93M | 457.27M | -256.72M | Operating Cash Flow |
-306.47M | -142.77M | -260.38M | -495.74M | 538.97M | -238.37M | Investing Cash Flow |
-202.44M | -280.48M | 374.65M | -258.65M | -1.04B | -541.17M | Financing Cash Flow |
36.64M | 331.98M | 62.66M | 38.59M | 250.94M | 1.02B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $2.02B | 12.71 | 24.71% | ― | 20.62% | 14.08% | |
60 Neutral | $3.59B | ― | -19.71% | ― | -86.13% | -67.29% | |
58 Neutral | $563.39M | ― | -34.26% | ― | 271.44% | 26.65% | |
54 Neutral | $5.41B | 3.27 | -45.10% | 3.29% | 16.81% | 0.02% | |
52 Neutral | $866.99M | ― | -57.92% | ― | -13.37% | 2.57% | |
52 Neutral | $1.61B | ― | -70.58% | ― | 100.03% | 64.22% | |
45 Neutral | $1.80B | ― | -38.04% | ― | -82.38% | -164.76% |
On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.
The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.
On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.